Role of bone-type tissue-nonspecific alkaline phosphatase and PHOSPO1 in vascular calcification

Current Pharmaceutical Design

Volumn 20, Issue 37, 2014, Pages 5821-5828

  Bobryshev, Yuri V ^a   Orekhov, Alexander N ^b,c   Sobenin, Igor ^c,d   Chistiakov, Dimitry A ^e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Institute for Atherosclerosis Research   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^e PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arterial calcification; Atherosclerosis; Bone type tissue nonspecific alkaline phosphatise; Mineralizing matrix vesicles; PHOSPO1; Vascular smooth muscle cells

Indexed keywords

ALKALINE PHOSPHATASE; HYDROXYAPATITE; PHOSPHATE; PHOSPHOPROTEIN PHOSPHATASE 1; ALPL PROTEIN, HUMAN; PHOSPHATASE; PHOSPHO1 PROTEIN, HUMAN;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; ENZYME ACTIVATION; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; BONE; ENZYMOLOGY; METABOLISM;

ALKALINE PHOSPHATASE; BONE AND BONES; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; VASCULAR CALCIFICATION;

EID: 84911462482     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140212193011     Document Type: Article

References (91)

1. Bonucci E. Bone mineralization. Front Biosci 2012; 17: 100-28.
2. Howlett CR. The fine structure of the proximal growth plate of the avian tibia. J Anat 1979; 128 (Pt 2): 377-99.
3. Sekikawa A, Shin C, Curb JD, et al. Aortic stiffness and calcification in men in a population-based international study. Atherosclerosis 2012; 222: 473-7.
4. Bobryshev YV, Killingsworth MC, Lord RS, Grabs AJ. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. J Cell Mol Med 2008; 12: 2073-82.
5. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 2010; 55: 579-92.
6. Sallam T, Cheng H, Demer LL, Tintut Y. Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci 2013; 70: 3187-97.
7. Doherty TM, Fitzpatrick LA, Inoue D, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25: 629-72.
8. Aigner T, Neureiter D, Câmpean V, Soder S, Amann K. Expression of cartilage-specific markers in calcified and non-calcified atherosclerotic lesions. Atherosclerosis 2008; 196: 37-41.
9. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26: 1423-30.
10. Clarke MC, Littlewood TD, Figg N, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-38.
11. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-62.
12. Bobryshev YV, Lord RS, Warren BA. Calcified deposit formation in intimal thickenings of the human aorta. Atherosclerosis 1995; 118: 9-21.
13. Bobryshev YV, Killingsworth MC, Huynh TG, Lord RS, Grabs AJ, Valenzuela SM. Are calcifying matrix vesicles in atherosclerotic lesions of cellular origin? Basic Res Cardiol 2007; 102: 133-43.
14. Bobryshev YV. Transdifferentiation of smooth muscle cells into chondrocytes in atherosclerotic arteries in situ: implications for diffuse intimal calcification. J Pathol 2005; 205: 641-50.
15. McCormick MM, Rahimi F, Bobryshev YV, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005; 280: 41521-9.
16. Anderson HC. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995; 314: 266-80.
17. Genge BR, Wu LN, Wuthier RE. In vitro modeling of matrix vesicle nucleation: synergistic stimulation of mineral formation by an-nexin A5 and phosphatidylserine. J Biol Chem 2007; 282: 26035-45.
18. Genge BR, Wu LN, Wuthier RE. Identification of phospholipid-dependent calcium-binding proteins as constituents of matrix vesicles. J Biol Chem 1989; 264: 10917-21.
19. Supuran CT. Carbonic anhydrases-an overview. Curr Pharm Des 2008; 14: 603-14.
20. Anderson HC. Matrix vesicles and calcification. Curr Pheumatol Rep 2003; 5: 222-6.
21. Roberts SJ, Owen HC, Farquharson C. Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1. Biochem Biophys Res Commun 2008; 371: 872-6.
22. Orimo H. The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 2010; 77: 4-12.
23. Zhou X, Cui Y, Zhou X, Han J. Phosphate/pyrophosphate and MV-related proteins in mineralisation: discoveries from mouse models. Int J Biol Sci 2012; 8: 778-90.
24. Addison WN, Azari F, Sørensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 2007; 282: 15872-83.
25. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289: 265-70.
26. Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002; 91: 9-16.
27. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66.
28. Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28: 81-91.
29. Swallow DM, Povey S, Parkar M, et al. Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1. Ann Hum Genet 1986; 50 (Pt 3): 229-35.
30. Anderson HC, Garimella R, Tague SE. The role of matrix vesicles in growth plate development and biomineralization. Front Biosci 2005; 10: 822-37.
31. Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 1988; 263: 12002-10.
32. Matsuura S, Kishi F, Kajii T. Characterization of a 5'-flanking region of the human liver/bone/kidney alkaline phosphatase gene: two kinds of mRNA from a single gene. Biochem Biophys Res Commun 1990; 168: 993-1000.
33. Sato N, Takahashi Y, Asano S. Preferential usage of the bone-type leader sequence for the transcripts of liver/bone/kidney-type alkaline phosphatase gene in neutrophilic granulocytes. Blood 1994; 83: 1093-101.
34. Whyte MP, Landt M, Ryan LM, et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoetha-nolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest 1995; 95: 1440-5.
35. Makita S, Al-Shawafi HA, Sultana S, Sohda M, Nomura S, Oda K. A dimerization defect caused by a glycine substitution at position 420 by serine in tissue-nonspecific alkaline phosphatase associated with perinatal hypophosphatasia. FEBS J 2012; 279: 4327-37.
36. Hooper NM. Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin Chim Acta 1997; 266: 3-12.
37. Narisawa S, Fröhlander N, Millán JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 1997; 208: 432-46.
38. Haarhaus M, Arnqvist HJ, Magnusson P. Calcifying human aortic smooth muscle cells express different bone alkaline phosphatase isoforms, including the novel B1x isoform. J Vasc Res 2013; 50: 167-74.
39. Magnusson P, Löfman O, Larsson L. Determination of alkaline phosphatase isoenzymes in serum by high-performance liquid chromatography with post-column reaction detection. J Chroma-togr 1992; 576: 79-86.
40. Magnusson P, Farley JR. Differences in sialic acid residues among bone alkaline phosphatase isoforms: a physical, biochemical, and immunological characterization. Calcif Tissue Int 2002; 71: 508-18.
41. Magnusson P, Larsson L, Magnusson M, Davie MW, Sharp CA. Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 1999; 14: 1926-33.
42. Kishi F, Matsuura S, Kajii T. Nucleotide sequence of the human liver-type alkaline phosphatase cDNA. Nucleic Acids Res 1989; 17: 2129.
43. Magnusson P, Arlestig L, Paus E, et al. Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop. Tumour Biol 2002; 23: 228-48.
44. Halling Linder C, Narisawa S, Millán JL, Magnusson P. Glycosyla-tion differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms. Bone 2009; 45: 987-93.
45. Villa-Bellosta R, Wang X, Millán JL, Dubyak GR, O'Neill WC. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2011; 301: H61-8.
46. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164: 1199-209.
47. Prosdocimo DA, Douglas DC, Romani AM, O'Neill WC, Dubyak GR. Autocrine ATP release coupled to extracellular pyrophosphate accumulation in vascular smooth muscle cells. Am J Physiol Cell Physiol 2009; 296: C828-39.
48. Ciancaglini P, Yadav MC, Simao AM, et al. Kinetic analysis of substrate utilization by native and TNAP-, NPP1-or PHOSPHO1-deficient matrix vesicles. J Bone Miner Res 2010; 25: 716-23.
49. Simão AM, Yadav MC, Narisawa S, et al. Proteoliposomes harboring alkaline phosphatase and nucleotide pyrophosphatase as matrix vesicle biomimetics. J Biol Chem 2010; 285: 7598-609.
50. Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010; 391: 1087-92.
51. Lencel P, Delplace S, Pilet P, et al. Cell-specific effects of TNF-α and IL-1 β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest 2011; 91: 1434-42.
52. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-7.
53. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009; 37: 847-54.
54. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, Chen D. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012; 221: 387-96.
55. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013; 13: 13.
56. Zeadin MG, Butcher MK, Shaughnessy SG, Werstuck GH. Leptin promotes osteoblast differentiation and mineralization of primary cultures of vascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3β. Biochem Biophys Res Commun 2012; 425: 924-30.
57. Al-Aly Z, Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-96.
58. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954-60.
59. Taylor J, Butcher M, Zeadin M, Politano A, Shaughnessy SG. Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 2011; 112: 581-8.
60. Suga T, Iso T, Shimizu T, et al. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb 2011; 18: 670-83.
61. Shimizu T, Tanaka T, Iso T, et al. Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: role of Msx2 gene induction via Notch-RBP-Jk signaling. Arterioscler Thromb Vasc Biol 2009; 29: 1104-11.
62. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glyca-tion end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-80.
63. Sutra T, Morena M, Bargnoux AS, Caporiccio B, Canaud B, Cristol JP. Superoxide production: a procalcifying cell signalling event in osteoblastic differentiation of vascular smooth muscle cells exposed to calcification media. Free Radic Res 2008; 42: 789-97.
64. Nishizawa Y, Jono S, Ishimura E, Shioi A. Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr 2005; 15: 178-82.
65. Orimo H, Shimada T. The role of tissue-nonspecific alkaline phosphatase in the phosphate-induced activation of alkaline phosphatase and mineralization in SaOS-2 human osteoblast-like cells. Mol Cell Biochem 2008; 315: 51-60.
66. Villa-Bellosta R, Rivera J, Osorio FG, et al. Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilford Progeria Syndrome that is Ameliorated upon Pyrophosphate Treatment. Circulation 2013; 127: 2442-51.
67. Ono H, Ichiki T, Fukuyama K, et al. cAMP-response element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2004; 24: 1634-9.
68. Lee GL, Chang YW, Wu JY, et al. TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production. Arterioscler Thromb Vasc Biol 2012; 32: 2751-60.
69. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636-42.
70. Prosdocimo DA, Wyler SC, Romani AM, O'Neill WC, Dubyak GR. Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010; 298: C702-13.
71. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-104.
72. Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res 2008; 23: 1798-805.
73. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489-94.
74. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-54.
75. Bobryshev YV, Killingsworth MC, Lord RS. Spatial distribution of osteoblast-specific transcription factor Cbfa1 and bone formation in atherosclerotic arteries. Cell Tissue Res 2008; 333: 225-35.
76. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-41.
77. Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem 2010; 110: 935-47.
78. Montes de Oca A, Madueño JA, Martinez-Moreno JM, et al. High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res 2010; 25: 1996-2005.
79. Stewart AJ, Schmid R, Blindauer CA, Paisey SJ, Farquharson C. Comparative modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid dehalogenase superfamily. Protein Eng 2003; 16: 889-95.
80. Roberts SJ, Stewart AJ, Sadler PJ, Farquharson C. Human PHOS-PHO1 exhibits high specific phosphoethanolamine and phospho-choline phosphatase activities. Biochem J 2004; 382(Pt 1): 59-65.
81. Kvam BJ, Pollesello P, Vittur F, Paoletti S. 31P NMR studies of resting zone cartilage from growth plate. Magn Reson Med 1992; 25: 355-61.
82. Millán JL. The Role of Phosphatases in the Initiation of Skeletal Mineralization. Calcif Tissue Int 2013; 93: 299-306.
83. Houston B, Paton IR, Burt DW, Farquharson C. Chromosomal localization of the chicken and mammalian orthologues of the orphan phosphatase PHOSPHO1 gene. Anim Genet 2002; 33: 451-4.
84. Stewart AJ, Roberts SJ, Seawright E, Davey MG, Fleming RH, Farquharson C. The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization. Bone 2006; 39: 1000-7.
85. Houston B, Seawright E, Jefferies D, et al. Identification and cloning of a novel phosphatase expressed at high levels in differentiating growth plate chondrocytes. Biochim Biophys Acta 1999; 1448: 500-6.
86. Houston B, Stewart AJ, Farquharson C. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage. Bone 2004; 34: 629-37.
87. Macrae VE, Davey MG, McTeir L, et al. Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick. Bone 2010; 46: 1146-55.
88. Yadav MC, Simão AM, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011; 26: 286-97.
89. McKee MD, Yadav MC, Foster BL, Somerman MJ, Farquharson C, Millán JL. Compounded PHOSPHO1/ALPL Deficiencies Reduce Dentin Mineralization. J Dent Res 2013; 92: 721-7.
90. Huesa C, Yadav MC, Finnilä MA, et al. PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. Bone 2011; 48: 1066-74.
91. Delomenède M, Buchet R, Mebarek S. Lansoprazole is an uncompetitive inhibitor of tissue-nonspecific alkaline phosphatase. Acta Biochim Pol 2009; 56: 301-5.